Gene therapy for neurological, and in particular neurodegenerative, disease is now a reality. A number of early phase clinical trials have been completed and several are currently in progress. In view of this, it is critically important to evaluate the immunological risk associated with neurological gene therapy, which has clear implications for trial safety and efficacy. Moreover, it is imperative in particular to identify factors indicating potential high risk. In the light of recent advances in understanding immune regulation in the central nervous system (CNS) and with the continued development of new gene delivery vectors, this review critically assesses the current knowledge of immunobiology within the CNS in terms of likely immunological risk pertaining to viral vectors and gene therapy applications for neurodegenerative disease.
Introduction
Although immune responses to gene therapy vectors in the central nervous system (CNS) are in general subdued, the parameters that determine such responses are similar to those governing immune responses outside the CNS. Importantly, results from preclinical studies in animals and recent data from clinical trials have shown the induction of both innate and adaptive immune responses in the CNS, with consequent implications for gene therapy clinical trials, including for viral vector safety, transduction efficiency and transgene expression. Thus, immunological factors are critical determinants of gene therapy clinical trial safety and also, ultimately, for trial efficacy. There are further CNS-specific considerations. A viable gene therapy targeting a chronic neurodegenerative disease such as Parkinson's disease (PD) is very likely to require vector re-administration in the long term. Moreover, such neurodegenerative diseases are typically associated with ongoing local inflammation, and to what extent such preexisting CNS inflammation increases the immunological risk for gene therapy must be critically evaluated. To date, the completed and ongoing trials have involved small numbers of patients treated over short periods relative to disease duration. Thus, the identification of specific circumstances and patient subgroups at potentially higher immunological risk will require better understanding of disease biology over the long term, and its impact on the likely success of a gene therapy intervention. Such evaluations of clinical risk must also be made in the light of greater knowledge of immunobiology within the CNS. Recent advances in the understanding of pathogen recognition have shown that viral vectors interact with innate immune sensing systems, and further that all neuronal and glial cell types within the CNS express such pathogen recognition receptors. This has implications for the mechanism and scope of both innate and adaptive immune responses to be anticipated in neurological gene therapy clinical trials. In addition, emerging evidence also suggests that microRNA (miRNA)-mediated gene regulation represents a fundamental layer of posttranscriptional regulation that has diverse functional tasks in viral immune regulation and likely in regulation of host immune responses to viral vectors. This review critically assesses and identifies key components of likely immunological risk pertaining to viral vector and gene therapy applications for neurological disease.
Current understanding of the immune responses in the CNS
The CNS has long been considered an immunologically privileged site. This is due to (1) the presence of the blood-brain barrier (BBB); [1] [2] [3] (2) the absence of resident lymphocytes and lack of conventional lymphatics; (3) low levels of major histocompatibility complex (MHC) class I and II molecules and a low preponderance of antigen-presenting cells (APCs), such as dendritic cells and macrophages 4, 5 and (4) the existence of local immunosuppressive factors and the expression of Fas ligand that induces apoptosis of activated T cells. Although the brain parenchyma normally lacks dendritic cells, and impairs priming of the adaptive immune response, as first shown by Lowenstein and co-workers, dendritic cells do appear in the brain parenchyma on inflammation. It is not yet clear whether these dendritic cells develop from microglia or another brain-resident precursor, or are recruited from the blood. It is also known that in the absence of other competent APCs, B cells and astrocytes are able to function as APCs and it is accepted that they have an important function in viral immunity in the brain. 6 Astrocytes, in an inflammatory environment, have the capacity to express the required MHC class II and B7 costimulatory molecules for efficient activation of naive T cells. B cells constitutively express MHC class II and B7 costimulatory molecules and B cells can also convert dendritic cells into antigenspecific APCs by promoting opsonization.
Microglia are the main innate immune cells of the brain and are the principle mediators of inflammation. In the presence of an activating stimulus, microglial cellsurface receptor expression is modified and the cells change from a monitoring function to one of protection and repair. Activated microglia secrete a variety of inflammatory mediators, including cytokines (tumor necrosis factor, and interleukin (IL)-1b and IL-6) and chemokines (macrophage inflammatory protein-1a, monocyte chemoattractant protein-1 and interferoninducible protein) that promote the inflammatory state. Similar to macrophages, microglial cells express Toll-like receptors (TLRs) and respond to TLR ligands that initiate production of pro-inflammatory mediators. In fact the discovery of pathogen recognition receptors such as the TLRs in the last decade heralded a revolution in the understanding of the innate immune system and has shed new light on how inflammatory responses are initiated and regulated within the CNS. 7 Perhaps surprisingly, all CNS cell types, including neurons, express these receptors and their ligation is important in regulating immune privilege as it enables a rapid response to infection, and provides a critical link between innate and adaptive immunity. [8] [9] [10] [11] [12] After activation of these receptors, the release of pro-inflammatory cytokines and chemokines activates the adaptive immune response. 13 The adaptive immune response involves interaction of T-cell receptors with antigen in the context of MHC molecule-peptide complexes in the nanometer scale gap between T cells and APCs, referred to as an immunological synapse. T-cell activation also requires a costimulatory signal involving interaction of CD28 on the T-cell with CD80 or CD86 (B7 family genes) on the APC. The existence of mature-type immunological synapses in the brain, indicative of T-cell responses in vivo, was first described by Lowenstein and co-workers and shown to occur during an immune-mediated elimination of adenovirally infected cells. Anti-adenoviral CD8 T cells infiltrated the brain and formed mature immunological synapses with MHC class I expressing astrocytes. The cell-cell communication at such synapses is situation-adapted and one of the main physiological functions of immunological synapses is to direct cytokine secretion either directly into the synapse or in a multidirectional manner outside the synapse. In the brain immunological synapses implement cytokine secretion directly into the synapse and 50% of infected astrocytes are eliminated after delivery of an adenoviral vector to the brain. 14, 15 The challenge in the CNS is to understand a response that must balance defense against invading pathogens with inflicting CNS injury. Thus, the concept of immune privilege has been refined and the CNS can now be more accurately described as an immune-attenuated site, as the machinery to initiate an immune response is present, 7 and in certain situations, robust immune responses can and do occur in response to pathogens and in autoimmune disease. [16] [17] [18] Advances in the understanding of the innate immune system and of RNA gene silencing pathways in the CNSimplications for gene therapy vectors
The innate immune response receptors are now known to be widely expressed in the CNS and constitute the first line of defense against viruses. 10, 19 Envelope glycoproteins of HSV activate cytokine responses through TLR2. TLR9 recognizes unmethylated CpG DNA motifs present in the adenovirus genome and responds to Immunobiology of gene therapy for neurodegenerative disease MM McMenamin and MJA Wood ligation by increasing pro-inflammatory cytokine secretion. [20] [21] [22] Single-stranded RNA derived from lentivirus activates TLR7 or TLR8 and leads to production of interferon-a and other cytokines in dendritic cells. 23 Although TLRs constitute the main sensors for detection of viruses two other distinct families, (1) the retinoic acid-inducible gene-like helicases and (2) the nucleotide-binding oligomerization domain-like receptors, act as intracellular surveillance receptors and have been implicated in viral dsRNA recognition. 24, 25 Nucleotide-binding oligomerization domain-like receptors recruit the inflammatory caspase-1 into innate cytosolic molecular complexes termed inflammasomes. Once activated, caspase-1 processes pro-IL-1b and pro-IL-18 to their active and secreted forms. The inflammasome has been shown to have a central function in the innate immune response to adenovirus; internalized adenoviral DNA induces maturation of pro-IL-1b in macrophages, which is dependent on components of the inflammasome. 23 The apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) family of cytidine deaminases is also expressed in all the major cellular constituents of the CNS and inhibits virus replication. APOBEC-3G/3F inhibits replication in endothelial cells of HIV-1, equine infectious anemia virus and murine leukemia virus. 26 An APOBEC3A protein hA3A targets adeno-associated virus (AAV) by inhibiting its replication (for summary see Figure 1a ).
Emerging evidence also suggests that RNA gene silencing pathways are important in regulating hostvirus interactions. [27] [28] [29] Host cellular miRNAs modulate viral gene expression and viral gene silencing mechanisms enable host immune evasion and can exploit the cellular miRNA pathway to their own advantage. 30 Work on wild-type viruses has shown that viral miRNAs inhibit aspects of the host-adaptive immune response, including antigen presentation, the innate immune response including induction of apoptosis or the interferon system. 28 Because most of the modified viruses used for gene therapy have genes encoding miRNAs deleted, this may be of importance in preventing them from evading the immune response and therefore leaving them more susceptible to immune attack, unlike their wild-type counterparts. In addition, replication of viruses can also be inhibited by endogenous cellular miRNAs but this control is unlikely to be extended to viral vectors because genes encoding the target viral transcripts will not be expressed or will be deleted in viral vectors. Although most of the work to date on miRNA modulation of host-virus responses has been undertaken with respect to wild-type viral infections outside the CNS, aspects of these findings are of potential relevance to CNS viral infections and to the function of gene therapy vectors within the CNS. A full understanding of the implications of miRNAs in relation to gene therapy vectors awaits further investigation (for summary see Figure 1b) .
In summary, a complex repertoire of factors is involved in regulating and determining the immune response to viruses in the CNS. This immune regulation is finely balanced and inappropriate activation can result in a pathogenic rather than a protective outcome. 19 It is important to understand in what circumstances robust immune activation can occur and what critical triggers initiate it.
Neurodegenerative diseases and aging are typically associated with ongoing local innate immune activity that may increase immunological risk Increasing evidence indicates that chronic neuroinflammation has a critical function in the pathogenesis of most neurodegenerative diseases. PD, Alzheimer's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, tauopathies and age-related macular degeneration are all associated with chronic neuroinflammation and elevated levels of several cytokines. 12, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] In addition, there are several recent reports that show normal aging is accompanied by progressive alterations in immune function. 41 Increased innate immune activity, microglial and immune cell activation and increased pro-inflammatory cytokine expression/release are found in brains of patients with PD and inflammation is thought to be a major contributor to the ongoing neurodegeneration and disease progression. 42, 43 Patients with Alzheimer's disease and a mouse model of Alzheimer's have been shown to have increased BBB permeability. 44, 45 Patients have also been shown to have TLR induction, 46, 47 activated microglia 48 and upregulated expression of cytokines, chemokines and chemokine receptors. 49 In diseased individuals with neuroinfections, such has HIV, the BBB has been shown to be more permeable. More generally, age-related immunosenescence includes increased BBB permeability 50, 51 and increased microglial and astrocytic activity. 52 Neuropathological and neuroradiological studies indicate that neuroinflammatory responses may begin before significant loss of neuronal populations in the progression of these diseases. Although there is no evidence to support a function for any particular cytokine in the direct triggering of any of these neurodegenerative conditions, cytokine-driven neuroinflammation and neurotoxicity has been shown to modify disease progression in a number of these disorders. [42] [43] [44] [46] [47] [48] [49] [50] [51] [52] Regardless of the initiating factor once an inflammatory response is initiated if left unresolved, it may contribute to death of vulnerable neuronal populations.
These changes in the aging brain can result in greater susceptibility and sensitivity to infection or immune stimulants. 41 A number of reports shows that a systemic immune challenge has the ability to modulate the immune response in the brain and that this is more exaggerated in an aged individual. Systemic administration of a peripheral toxin such as staphylococcal enterotoxin A in an animal model shows that as well as engaging the innate arm of the immune response activated T cells also exert neuromodulatory effects. 53 Staphylococcal enterotoxin A increased levels of IL-1b in the aged, but not young, mice 2 h after administration. 54 Stimulation of the peripheral innate immune system in aged Balb/c mice causes exaggerated neuroinflammation. 55 MHC class II expression was increased specifically in aged microglia, causing them to maintain a reactive or primed phenotype. Peripheral lipopolysaccharide injection in mice caused microglia overexpression of TLR2 and resultant induction of pro-inflammatory cytokines compared to adults. 56 Earlier work showed that systemic and central endotoxin challenges exacerbate the local Immunobiology of gene therapy for neurodegenerative disease MM McMenamin and MJA Wood brain inflammatory response and increase neuronal death during chronic inflammation. 41, 55 If a systemic immune challenge can modulate an immune response in the aged brain, it is very likely that the aged brain will be more susceptible to an immune challenge in the context of a gene therapy vector delivered directly to the brain.
Given that a major focus of CNS gene therapy will be to treat neurodegenerative disease, the implications of increased inflammation associated with the disease process and general age-related immunosenesence should be considered and their risk assessed. If the immune system is already activated, preexisting inflammation might (1) increase the risk of an immune response to a gene therapy vector and/or (2) immune responses elicited by gene therapy vectors might exacerbate the target neurodegenerative disease process. In summary, treatment of aged individuals with ongoing neurodegenerative disease is likely to increase the risk of an immune response with gene therapy vectors.
CNS immune response to gene therapy vectors depends on vector type, vector dose and transgene
As discussed above the CNS is immune attenuated and the innate immune/inflammatory status can be influenced both by patient age and whether there is ongoing disease With gene therapy vectors, the likelihood of immune activation depends on the immune stimulus, that is, the properties of the relevant gene therapy vectors and the host status. Although the main gene therapy vectors in use for the CNS are viral vectors, The initial product is a transcript that contains one or more stemmed looped structures, known as a primary miRNA (pri-miRNA). The nuclease Drosha cleaves the pri-miRNA stem, excising hairpin loops known as precursor miRNAs. These are exported to the cytoplasm and processed by another nuclease, Dicer, generating mature miRNAs of B22 nucleotides. The miRNAs are loaded into a protein complex known as the RNA-induced silencing complex (RISC), which they then guide to the target mRNA to exert their effector function. Binding of the RISC to an mRNA bearing extensive sequence complementarity to the miRNA generally results in mRNA cleavage and degradation whereas binding to mRNAs bearing partial complementarity results mainly in translational arrest. Viruses exploit the cellular miRNA-processing pathway to generate viral miRNAs and can saturate the system causing its suppression. Viral miRNAs can inhibit the expression of cellular genes including inflammatory genes and other cellular miRNAs with anti-viral activity, including miRNA biogenesis. Cellular miRNAs can inhibit viral gene expression. Viral vectors with many or all viral genes removed will be less susceptible to these controls; in particular they are unlikely to express viral miRNAs to inhibit of cellular inflammatory genes making the vectors potentially more immunogenic. The earliest gene therapy vectors, as shown principally by the Wood and Lowenstein laboratories, elicited both innate and adaptive CNS responses in normal animals. With HSV-derived vectors, the viral envelope glycoproteins were found to elicit a humoral immune response. In the case of adenovirus, an innate immune response was rapidly stimulated by viral capsid proteins. Even though the genes involved in replication and pathogenesis were removed from these vectors, they were still found to exhibit low levels of viral gene expression resulting in production of immunogenic viral gene products limiting their potential application for neurodegenerative disorder gene therapy. 57, 58 In view of the immune response elicited by such early vectors, the focus of attention in later generation vectors has been to reduce/eliminate viral gene expression to improve their clinical use. Hence more recently developed adenoviral vectors, with all viral genes deleted, AAV and lentiviral vectors are now being actively exploited for gene delivery to the CNS. Any immune response to such vectors should therefore only be elicited to the input virions and potentially the transgene. Because virion-derived proteins provide only a limited source of antigenic epitopes, any immune activation would be expected to be a self-limiting process. When a fully deleted adenovirus with all coding sequences deleted was injected into the mouse brain, inflammation was greatly diminished at 14 days after administration compared with a first-generation vector and had subsided by 30 days. In a separate study, in rats the numbers of macrophages and T lymphocytes infiltrating the brain were greatly reduced with fully deleted adenovirus vectors compared with earlier vectors.
Immunobiology of
AAV has considerable appeal as a gene therapy vector both in the periphery and CNS due to its reduced viral gene expression and low immunogenicity. Although AAV is devoid of viral-coding sequences the cloning capacity of AAV is limited, 4.8 kb as opposed to 35 kb with fully deleted adenovirus. A single administration of AAV in the brain or the periphery of a naive animal is considered to be minimally immunogenic. 59 AAV is also capable of infecting dividing and nondividing cells, and maintaining stable, long-term gene expression in differentiated cells, especially neurons. 60 Thus, neuronal transduction can theoretically provide protein production for several years, [61] [62] [63] which is a highly advantageous attribute when considering the treatment of long-term, progressive neurodegenerative disorders.
AAV serotype 2 (AAV2) has been the vector of choice for recent PD Phase I clinical trials aimed at delivery of neurturin, 64 glutamic acid decarboxylase 65, 66 and human aromatic l-amino-acid decarboxylase 62 (see summary in Table 1 ). These trials, while reporting encouraging safety data thus far, have involved only small numbers of patients and in some cases were dose escalation studies with only a limited number of patients receiving the highest vector dose. 65 Greater concern may be warranted with younger patients and in particular those where widespread vector administration is required (and thus a higher antigenic load delivered), such as in late infantile neuronal ceroid lipofuscinosis, an autosomal recessive, neurodegenerative lysosomal storage disease affecting the CNS. 67 Although there were no unexpected serious adverse events in this study unequivocally attributable to the vector, there were serious adverse effects, the etiology of which could not be determined. One subject died 49 days after surgery after developing status epilepticus on day 14, but with no evidence of CNS inflammation. Of the 10 subjects, 4 developed a mild, mostly transient, humoral immune response to the vector though none of the patients had detectable serum antibodies before treatment. However, caution is necessary because as yet there is no long-term clinical trial data available, the trials have been conducted on relatively few patients and they have not all been tested at higher vector doses.
Lentiviruses have also shown considerable promise for treatment of neurodegenerative disorders. The development of multiply deleted vectors in which the vast majority of the viral genome is removed has helped to minimize the induction of a host immune response. 68, 69 There are now numerous examples of effective long-term treatment of animal models of neurological disorders, such as PD, Alzheimer's disease, Huntington's disease, motor neuron diseases, lysosomal storage diseases and spinal injury, using a range of therapeutic genes expressed in lentiviral vectors. 68, 70 As yet, however, there are no data from the clinical trials (for summary see Table 1 ). Although such vectors were originally thought not to be an immunological risk, recent studies outside the CNS suggest that the therapeutic benefit of lentiviral-mediated gene therapy may be hindered by the activation of destructive T cells. 71 In a study in which GFP and luciferase reporter genes were used to study transgene-specific T-cell activation after lentivirus-mediated gene transfer to mouse lung, both transgenes were shown to elicit transgene-specific T cells in C57BL/6 and BALB/c mice. 71, 72 On account of this immunogenicity, lentiviruses are now being developed as novel genetic vaccines. [73] [74] [75] Although this study did not deal with the immune response to lentiviral vectors in the CNS, caution is also warranted for CNS delivery.
One of the most important factors influencing the immune response to viral vectors is the dose of vector injected. High vector doses have been shown to cause an increased immune response and neuropathological damage in the dopaminergic system of direct relevance to PD. 57, 58 With lower titers the immune response is greatly diminished at 14 days after administration and by 30 days immune activity is typically restricted to the site of vector injection. It is likely therefore that with the delivery of higher doses, more vector antigen finds its way into the CSF or blood where it can exit the CNS to local sites where antigen presentation is enabled. 76 Immune responses to the transgene could be detrimental to the host by not only preventing further gene therapy attempts but also by preventing the administration of therapeutic proteins. However, few studies have specifically addressed the question of whether the immune responses elicited by viral vectors in the CNS are directed exclusively against the transgene or against the transgene in addition to the vector. Recent work with AAV in the brain has shown that the antigen that sparks
Immunobiology of gene therapy for neurodegenerative disease MM McMenamin and MJA Wood a brain immune response to AAV2 is the capsid protein and not the transgene. 77 When lentiviral vectors have been injected into the CNS there was no measurable immune response to the transgene. However, systemic immunization with a lentiviral vector expressing the same transgene caused an infiltration of inflammatory cells into the CNS and it was shown that there was no immune response to the vector itself, only to the transgene antigenic epitopes. Lentiviral gene delivery of nerve growth factor leading to gene expression was detectable in non-human primate brains for at least 1 year after gene delivery, with no activation of inflammatory markers. 78 In summary, whether or not there is an immune response to the transgene depends to some extent on whether the gene product is syn-or xenogeneic, the latter being more immunogenic, and whether or not there has been a previous exposure to the gene product, which increases the risk of an exacerbated inflammatory response. 77 Previous exposure to the virus or re-introduction of the viral vector may suppress transgene expression and increase immunological risk Even with improved, less immunogenic vectors the preexisting state of the adaptive immune system will influence immunological risk/outcome. Two potentially high-risk situations should be considered: (1) previous exposure to the vector antigens, in particular if the exposure has taken place outside the CNS; and (2) where re-administration of vector is required.
Several studies have shown that peripheral infection with a gene therapy virus can severely compromise subsequent CNS gene delivery, as activated T and B lymphocytes readily cross the BBB under such conditions. Where there has been previous peripheral exposure to a virus such as adenovirus, a more severe inflammatory response is subsequently initiated in the brain resulting in elimination of the vector, than is seen after a local brain parenchymal injection alone. There is now evidence of a systemic immunization threshold for a dose that generates an immune response strong enough to eliminate transgene expression from the CNS. Once the threshold for systemic immunization is reached, the immune response eliminates transgene expression by 490% even from brains that receive as little as 1000 infectious units of adenoviral vectors. 76 In contrast, preexisting anti-adenoviral immunity is not a barrier to efficient and stable transduction of the brain by fully deleted adenovirus vectors. 76 Tetracycline-regulated high-capacity adenoviral vectors also sustain regulated transgene expression even in the presence of preexisting systemic immune though the mechanisms involved here are not clear. 79 Peripheral immunization of rats with wild-type AAV resulted in high levels of serum neutralizing antibodies and prevented transduction by AAV2 as assessed by striatal GDNF levels. However, transduction was not affected when AAV5 was used for the subsequent striatal injection. In all gene therapy clinical trials undertaken for CNS neurodegenerative disease to date, there have been no reports of any adverse events associated with the immune response. 67 In trials where subjects had preexisting neutralizing antibodies, no adverse immune events were noted. 63, 64, 65 However, in view of the chronic nature of neurodegenerative disease, it is highly likely that vector re-administration will need to be considered, which raises the question of whether this poses any additional immunological risk. When a first-generation adenoviral vector was re-administered to the same site in the brains of rats one month after an initial injection, this resulted in a damaging immune response and detectable neuronal cell death. 57 The During laboratory showed that re-administration of the same AAV to the CNS was possible but it depends on the interval between the first and second injection. In subsequent studies, although low-level immune responses were detected after intraparenchymal brain administration of AAV, repeat administration of the same vector serotype led to an increase in neutralizing antibodies, with conflicting reports between different studies of a reduction in transgene expression. In the most recent study in rats, intrastriatal re-administration of AAV2 clearly resulted in an intensified immune response in the second injection site. 77 In this study, a single administration of AAV expressing GFP was found to be minimally immunogenic but intrastriatal re-administration of the same vector and transgene resulted in an intensified immune response in the injection site showing that antigen presentation and priming of the immune system can and does occur in the brain. There was a 70% reduction in transduced cells expressing GFP and the presence of macrophages and CD8 T cells in the injection site suggested a T-cell-mediated immune response may have been responsible for the loss in transgene expression. 77 Therefore, at present vector re-administration is likely to constitute a significantly high immune risk in CNS gene therapy applications.
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Novel viral vectors further reduce immunological risk
The high-risk immune situations for neurodegenerative disease gene therapy are likely to be where the immune system is already compromised, the use of immunogenic viral vectors, high vector dose requirements, cases in which there is preexisting inflammation and ongoing progressive disease where continued treatment and vector re-administration may be required.
With improvements in vectorology newer vectors that are likely to reduce immune risk further continue to be engineered. [81] [82] [83] The most recent generation of adenoviral vectors allows the use of longer tissue-specific or regulatable promoters that can modulate the immune response. 84 Capsid modification with polyethylene glycol (PEGylation) reduced the innate immune response of fully deleted vectors in the periphery and therefore such modification also has potential for reducing the immune response in the CNS. 85 To evade an immune response to AAV vectors, capsid modification also holds promise. In addition, there are now several different serotypes of AAV in use for the CNS, which have greater and more widespread transduction efficiencies than earlier serotypes. [86] [87] [88] Thus, for a re-administration protocol an immune response against AAV2 capsid proteins can be circumvented by re-administration with a different serotype. 77 As well as human serotypes, non-human primate AAV serotypes such as AAV Rh10 have also been explored for delivery to the CNS. 89 In addition, by using directed evolution with a diverse array of novel AAV libraries, a new generation of AAV vectors capable of highly efficient delivery to astrocytes has been engineered. 90 Self-complementary AAV vectors, which bypass the required second-strand DNA synthesis to achieve transcription of the transgene have recently been used for retinal gene therapy without adverse immune responses. Transgene expression lasted for over 3.5 months in rats and 2.35 years in monkeys without any reported adverse effects in these studies. A number of non-HIV lentiviruses such as equine infectious anemia virus, simian immunodeficiency virus and feline immunodeficiency virus are also being developed. Equine infectious anemia virus has a high transduction capacity and limited adverse effects, is highly specific for gene transfer to adult neural stem cells and has been successfully used in neural tissue. 91 The quiescent and slow-dividing nature of adult stem cells was considered to be the likely basis of the affinity of these stem cells for lentivurses. Moreover, the use of miRNAs to regulate vector tropism may provide a valuable tool for viral vectors to evade the immune system and allow repeated vector administration. 92 miRNA targeting involves engineering the viral genome to contain miRNA target (miRT) elements that can then be recognized and regulated by endogenous cellular miRNAs or, possibly, viral miRNAs. miRNA targets could possibly decrease antigen presentation that could dampen an antiviral immune response. It seems likely that viral miRNAs could be designed against many targets (both cellular and viral) to enhance the performance of viruses. Potential targets that would limit natural killer-mediated recognition, limit viral antigen presentation, control the interferon response, suppress inflammatory cytokine release and inhibit cellular apoptosis, could prove to be of particular importance.
In summary, the latest vectors have been refined to reduce immunogenicity by having all the viral genomic sequences removed and can be produced safely for the clinic. 68 Despite such improvements in vector design, there are still reports of immune responses in certain situations and some of these relate to specific host factors, such as species, disease status or age, that in the clinical situation are unalterable variables. One clearly identifiable risk factor is previous exposure to the virus or the requirement for repeat delivery; thus, caution must be observed and individuals evaluated with the knowledge of situations likely to constitute higher risk.
Prospects
Within the near future, data should emerge from the Phase I/II trials using a range of different gene therapy vectors for neurodegenerative disease. As well as providing possible efficacy data, these trials should inform directions required for further research into gene therapy vectors, and for the CNS in particular, any adverse immune events caused by the vectors that and identifying the target host proteins of such viral inhibitors could provide valuable insights into how to engineer gene therapy vectors successfully to evade the immune response. The use of novel vector serotypes and novel chemical formulations or methods for immunosuppression are all potentially important in this regard. An increased understanding of miRNA-mediated gene regulation should also provide insight into virus-host interactions and the regulatory control of the innate immune response of direct relevance to developing safer gene therapy vectors and protocols. Improved understanding should potentially provide therapeutic strategies for immune response regulation and targets for pharmacological intervention. By incorporating target sites for a specific miRNA into a transgene or the genome of a virus, transgene expression becomes susceptible to regulation in cells in which that miRNA is expressed and may provide a novel strategy to prevent transgene expression in nontarget cells, for example APCs. 94 The major immunological risks for CNS gene therapy applications are (1) where the immune system is already activated in an aged individual or in the case of ongoing chronic disease, (2) where there has been previous exposure to the virus or vector and (3) instances or protocols where vector re-administration is required. Individuals may respond differently depending on their disease and immune status, which may require tailoring treatments accordingly. Strategies to limit the immune response therefore need to be designed and tested with these findings in mind. Where patients have preexisting antibodies or cytotoxic T cells to a vector from a previous wild-type exposure, these levels should be carefully monitored in view of data from peripheral gene therapy trials, as both innate immune responses to adenovirus challenge and preexisting adenovirus immunity represent fundamental problems, with great implications for both safety and efficacy of adenovirus vector gene therapy applications. 85, 95 In a recent clinical trial involving an adenoviral-based vaccination against HIV individuals with preexisting immunity to adenovirus showed preferential expansion of activated CD4 cells, increasing the number of virus targets and leading to higher susceptibility to HIV infection. 95 Thus, for the purposes of virus delivery to people with a previous exposure to the vector, the problem may be overcome by using vectors from rarer serotypes. For re-administration, it will almost certainly be necessary to use a different vector serotype for subsequent deliveries or to include an immunosuppressive agent within the treatment protocol. Where the transgene contributes to immunogenicity, the potential deleterious effects could be minimized with the use of inducible promoters and tight regulation.
Conclusion
There has been much progress in recent years in reducing the immunogenicity of viral vectors for delivery to the CNS. However, there remain potential risks, in chronic disease states in aged individuals with activated immune systems, in particular where there has been earlier exposure to the vector or where readministration is required. Although systematic studies in animal models are useful, it is not always possible to extrapolate from these to the clinical situation and thus a critical awareness of potential high-risk situations is imperative in the design and conduct of future clinical trials. 
